ha-irinotecan phase 3 trial update , page-4

I suppose they can't say a lot, given the double blind design. But there are a few take home points.

* No safety/efficacy problems. We already knew that from PhII, but nice to have it reinforced.

* "...the data presented to the DSMB is consistent with that expectation [improved benefit without increased burden of toxicity]..." That sounds like a preliminary thumbs-up. That's my favorite bit.

* increased recruitment to stay on schedule. ie they still expect to complete within the planned timeframe.

All good!